Early Detection of Thrombin Activity in Neuroinflammatory Disease

Dimitrios Davalos, PhD,1 Kim M. Baeten, PhD,1 Michael A. Whitney, PhD,2 Eric S. Mullins, MD,3 Beth Friedman, PhD,2 Emilia S. Olson, MD, PhD,2 Jae Kyu Ryu, PhD,1 Dimitri S. Smirnoff,1 Mark A. Petersen, MD,1,4 Catherine Bedard, MS,1 Jay L. Degen, PhD,3 Roger Y. Tsien, PhD,2,5,6 and Katerina Akassoglou, PhD1,7

Although multiple sclerosis (MS) has been associated with the coagulation system, the temporal and spatial regulation of coagulation activity in neuroinflammatory lesions is unknown. Using a novel molecular probe, we characterized the activity pattern of thrombin, the central protease of the coagulation cascade, in experimental autoimmune encephalomyelitis. Thrombin activity preceded onset of neurological signs, increased at disease peak, and correlated with fibrin deposition, microglial activation, demyelination, axonal damage, and clinical severity. Mice with a genetic deficit in prothrombin confirmed the specificity of the thrombin probe. Thrombin activity might be exploited for developing sensitive probes for preclinical detection and monitoring of neuroinflammation and MS progression.

Materials and Methods

EAE was induced by MOG35–55 immunization as described,6 in cohorts of Cx3cr1GFP/1 microglia reporter6 or Mx1-Cre:fIIlox/lox21 microglia reporter. From the 1Gladstone Institute of Neurological Disease, University of California, San Francisco, San Francisco, CA; 2Department of Pharmacology, University of California, San Diego, La Jolla, CA; 3Cancer and Blood Diseases Institute, Division of Experimental Hematology, University of Cincinnati College of Medicine, Cincinnati, OH; 4Division of Neonatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA; 5Howard Hughes Medical Institute, University of California, San Diego, La Jolla, CA; 6Department of Neurology, University of California, San Francisco, San Francisco, CA.

Address correspondence to Dr Akassoglou, Gladstone Institute of Neurological Disease, University of California, San Francisco, 1650 Owens St, San Francisco, CA, 94158. E-mail: kakassoglou@gladstone.ucsf.edu

Additional Supporting Information may be found in the online version of this article.

Received Sep 20, 2013, and in revised form Nov 7, 2013. Accepted for publication Nov 23, 2013.

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24078

© 2014 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of Child Neurology Society/American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
mice, which were also injected with poly-I:C, and were all of C57BL/6 background. Our molecular probe, termed PPRSFL-ACPP, consists of the thrombin-specific cleavage sequence, PPRSFL, which links a polycationic cell-penetrating peptide tagged with Cy5 to a neutralizing polyanion. In the presence of active thrombin, the linker is proteolyzed, resulting in absorption and uptake of the Cy5-labeled peptide into cells. One hundred microliters of 100 μM Cy5-labeled thrombin-cleavable PPRSFL or control methoxy poly(ethylene glycol) (mPEG)-ACPP show specific uptake (dark spots) of PPRSFL-ACPP, indicative of increased localized thrombin activity at the peak of EAE. Uninjected healthy control and EAE mice are also shown as controls (no probe). (B) Quantification of total fluorescent signal in whole spinal cord scans from A, corrected for size. Data are presented as mean ± standard error of the mean (SEM); ***p < 0.001, 2-way analysis of variance (ANOVA); n = 5 to 7 per group for no probe or PPRSFL-ACPP and 2 to 3 for mPEG-ACPP. (C) Genetic reduction or elimination of prothrombin abolishes localized thrombin activity detection in EAE. Whole spinal cord scans from 3 cohorts of mice injected with PPRSFL-ACPP and poly-I:C at EAE peak: wild-type (WT; 100% prothrombin), Mx1Cre(−)fllox/lox (20% prothrombin), and Mx1Cre(+)fllox/lox (no prothrombin). Prior to Cre recombinase induction, homozygous Mx1-Cre:fllox/lox mice exhibit baseline circulating prothrombin levels that are ∼20% of normal, whereas intraperitoneal injection of poly-I:C over a 6-day period results in a rapid loss of hepatic prothrombin expression and a near-complete loss (<5%) of circulating prothrombin within 5 to 6 days. Poly-I:C was administered at the time of overt clinical disease onset. (D) Quantification of PPRSFL-ACPP signal in whole spinal cord scans from C shows significantly reduced PPRSFL-ACPP retention with lower thrombin levels. Data are presented as mean ± SEM; ***p < 0.0001, 1-way ANOVA; n = 5 to 6 per group.

FIGURE 1: Specific detection of thrombin activity in the experimental autoimmune encephalomyelitis (EAE) spinal cord. (A) Whole spinal cord scans at 700 nm from mice at peak EAE or healthy controls, injected with Cy5-labeled thrombin-specific PPRSFL-activatable cell-penetrating peptide (ACPP) or Cy5-labeled noncleavable control methoxy poly(ethylene glycol) (mPEG)-ACPP show specific uptake (dark spots) of PPRSFL-ACPP, indicative of increased localized thrombin activity at the peak of EAE. Uninjected healthy control and EAE mice are also shown as controls (no probe). (B) Quantification of total fluorescent signal in whole spinal cord scans from A, corrected for size. Data are presented as mean ± standard error of the mean (SEM); ***p < 0.001, 2-way analysis of variance (ANOVA); n = 5 to 7 per group for no probe or PPRSFL-ACPP and 2 to 3 for mPEG-ACPP. (C) Genetic reduction or elimination of prothrombin abolishes localized thrombin activity detection in EAE. Whole spinal cord scans from 3 cohorts of mice injected with PPRSFL-ACPP and poly-I:C at EAE peak: wild-type (WT; 100% prothrombin), Mx1Cre(−)fllox/lox (20% prothrombin), and Mx1Cre(+)fllox/lox (no prothrombin). Prior to Cre recombinase induction, homozygous Mx1-Cre:fllox/lox mice exhibit baseline circulating prothrombin levels that are ∼20% of normal, whereas intraperitoneal injection of poly-I:C over a 6-day period results in a rapid loss of hepatic prothrombin expression and a near-complete loss (<5%) of circulating prothrombin within 5 to 6 days. Poly-I:C was administered at the time of overt clinical disease onset. (D) Quantification of PPRSFL-ACPP signal in whole spinal cord scans from C shows significantly reduced PPRSFL-ACPP retention with lower thrombin levels. Data are presented as mean ± SEM; ***p < 0.0001, 1-way ANOVA; n = 5 to 6 per group.
Results

Specific Detection of Active Thrombin in EAE Using the PPRSFL-ACPP

To examine whether thrombin is locally activated in the CNS in neuroinflammation, we administered the thrombin-cleavable PPRSFL-ACPP\(^{18}\) to EAE-challenged mice with overt impairment in motor function.\(^5,6\) Thrombin activity dramatically increased at the peak of disease in the spinal cord, a major CNS site of disease pathology in EAE\(^6\) (Fig 1A). Imaging of whole excised spinal cords revealed multiple hot spots of PPRSFL-ACPP uptake in EAE, implying increased localized thrombin activity, which was \(\sim 3.5\)-fold higher at disease peak compared to noninjected or healthy controls (\(p < 0.001\)) (Fig 1B). Signal was not detected in healthy mice or at peak of EAE after administration of control methoxy poly (ethylene glycol) (mPEG) mPEG-ACPP.

The PPRSFL-ACPP was also tested for thrombin-dependent activity in the CNS in vivo in EAE mice with genetically reduced or eliminated prothrombin (\(Mx1-Cre^{flox/lox}\)).\(^{21}\) Genetic reduction of prothrombin plasma levels significantly reduced PPRSFL-ACPP detection in the spinal cord of mice at EAE peak (Fig 1C). Quantification showed \(\sim 5.6\) and \(\sim 6.8\) fold reduction for mice with 20% and 0% of normal prothrombin levels, respectively, relative to wild-type controls, providing genetic confirmation that the PPRSFL-ACPP is thrombin-specific (Fig 1D). The thrombin specificity of PPRSFL-ACPP was also previously shown using thrombin inhibitors in animal models of stroke and atherosclerosis, as well as in vitro by cleavage experiments with a spectrum of other proteases, including Factor Xa and matrix metalloproteinase (MMP)-9.\(^{18–20}\)

Thrombin Activation Occurs Early and Correlates with Disease Progression in Neuroinflammation

We further sought to examine the temporal regulation of thrombin activity and its correlation with neuroinflammatory disease progression. We administered thrombin probe in mice at 3 stages of EAE: before neurological signs, at early onset, and at disease peak (Fig 2). In whole spinal cord scans thrombin activity was detected before symptoms appeared and gradually increased at onset and peak of neurologic signs. Compared to healthy controls, thrombin activity was significantly increased both at disease onset during the appearance of the earliest neurologic signs and also at disease peak. There was a linear correlation between thrombin activity and the severity of neurological signs (\(R^2 = 0.86, p < 0.0001\), F test), suggesting that thrombin activity is detected early and is a molecular marker of disease progression in neuroinflammation.

Thrombin Activity Is a Marker of Fibrin-Laden Inflammatory Demyelinated Lesions with Axonal Damage

We previously showed that microglia form perivascular clusters at sites of fibrin deposition prior to myelin loss or paralysis onset in EAE.\(^6\) Thrombin activity was detected in spinal cords as early as the onset of EAE within regions with microglial activation and fibrin deposition (Fig 3A). At the peak of EAE, thrombin activity was specifically detected in areas with extensive fibrin deposition and microglial

\[\text{FIGURE 2: Uptake of PPRSFL–activatable cell-penetrating peptide (ACPP) correlates with disease progression and neurologic symptoms. (A) Representative experimental autoimmune encephalomyelitis (EAE) clinical score curve illustrates the different time points of PPRSFL-ACPP administration. (B) Quantification of total fluorescent signal in whole spinal cord scans from mice injected with PPRSFL-ACPP at different time points of EAE shows that detection of thrombin activity increases with EAE progression. Data are presented as mean ± standard error of the mean; \(* p < 0.05, *** p < 0.001\), 1-way analysis of variance; \(n = 5\) to 7 per group. (C) Scatter plot shows correlation between total thrombin activity in the entire spinal cord and clinical score of EAE (\(R^2 = 0.86, p < 0.0001\), F test). [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]}\]
FIGURE 3: Increased thrombin activity in experimental autoimmune encephalomyelitis (EAE) spatially correlates with blood–brain barrier (BBB) disruption, microglial activation, demyelination, and axonal damage. (A) Confocal microscopy of spinal cord sections from Cx3cr1<sup>GFP/</sup> mice showing the spatial and temporal correlation between thrombin activity (PPRSFL–activatable cell-penetrating peptide [ACPP], red), areas of BBB disruption (fibrinogen deposition, cyan) and local inflammation (green fluorescent protein–labeled microglia, green) at onset or peak of EAE. Healthy Cx3cr1<sup>GFP/</sup> controls with no signs of microglial activation or fibrin deposition show no thrombin activity. (B) Single-plane analysis of image stacks acquired at high magnification with confocal microscopy showed that microglia (green) uptake a significant amount of the thrombin-sensitive PPRSFL-ACPP (red) in neuroinflammatory lesions. (C) Thrombin activity correlates with areas of demyelination in EAE lesions, at the peak of disease. Confocal images of spinal cord sections immunohistochemically stained for myelin basic protein (MBP, cyan) show that thrombin activity (PPRSFL-ACPP, red) is pronounced in white matter areas where myelin is damaged. Dotted line indicates area of parenchymal demyelination, and stars indicate perivascular demyelination sites. (D) Confocal images of spinal cord sections stained with anti–SMI-32 (cyan), a marker for axonal damage not detected in healthy spinal cords, show that thrombin activity (PPRSFL-ACPP, red) is pronounced in white matter areas with extensive signs of axonal damage. Bars represent: A, 50 μm; B, 5 μm; C, 50 μm; D, 20 μm. (E–G) Scatter plots show positive correlation between thrombin activity (PPRSFL-ACPP signal) and fibrinogen (E; R² = 0.55, p < 0.001, F test), microglial activation (F; R² = 0.35, p < 0.01, F test), and demyelination (G; R² = 0.52, p < 0.01, F test) in spinal cords at the peak of EAE.
clustering, but not in healthy controls. PPRSFL-ACPP thrombin cleavage product was consistently taken up within inflammatory lesions by cells including but not limited to microglia (Fig 3B). Moreover, increased thrombin activity was detected in multiple inflamed spinal cord areas at the peak of EAE (Supplemental Fig 1), whereas retention of non-specific probe was undetectable at sites of inflammation or BBB disruption (Supplemental Fig 2).

In active EAE and MS lesions, fibrin deposition correlates with axonal damage and demyelination. The thrombin inhibitor hirudin reduces clinical severity, microglial activation, demyelination, and axonal damage in EAE. Thrombin activity was detected within demyelinated lesions at the peak of EAE (Fig 3C) in areas with microglial activation (Supplemental Fig 3) and prominent axonal damage (Fig 3D). Quantification showed strong correlation between thrombin activity and fibrin deposition ($R^2 = 0.55$, $P < 0.001$, F test), increased microglial activation ($R^2 = 0.35$, $P < 0.01$, F test), and the size of demyelinated lesions ($R^2 = 0.52$, $P < 0.01$, F test) at disease peak. Overall, these results suggest that thrombin activation occurs early in EAE and is a specific marker of inflammatory demyelinated lesions.

**Discussion**

The present study demonstrates that a thrombin-specific ACPP detects inflammatory demyelination in vivo. We show strong association between thrombin activity and BBB disruption, microglial activation, inflammatory demyelination, and axonal damage. Intriguingly, thrombin activation begins early at disease onset, prior to demyelination, and correlates with disease progression. Together with prior studies showing BBB disruption and deposition of fibrin early in EAE and MS, these results suggest that activation of the coagulation cascade occurs at the earliest signs of inflammatory activity in lesions prior to demyelination.

Association of thrombin activity with sites of increased vascular permeability might indicate that the main source of thrombin in EAE is plasma-derived. It is possible that upon BBB disruption fibrinogen together with prothrombin enter the CNS and local activation of thrombin results in fibrin deposition. However, because prothrombin RNA can be expressed by neurons and microglia, we cannot rule out the possibility that prothrombin might also be produced in situ in neuroinflammation. Pharmacological studies have demonstrated a pathogenic role of thrombin in EAE, as its inhibition by hirudin protects from neurological signs, demyelination, and axonal damage. Thrombin might be pathogenic by catalyzing the formation of fibrin, which is a major activator of microglia and an enabler of inflammatory demyelination. Our data show that thrombin activation can be detected at sites of fibrin deposition both at onset and at the peak of neuroinflammation. Studies using mice genetically deficient for fibrinogen or fibrin inhibitors that do not interfere with thrombin activation show protection from EAE, suggesting that generation of fibrin is a major pathogenic mechanism of thrombin activation. However, it is also possible that thrombin might exert fibrin-independent effects through activation of protease-activated receptors, which are expressed in several CNS cells. Future studies will determine the relative contribution of local thrombin synthesis and the mechanisms of action of thrombin in neuroinflammation.

Our work is a proof-of-principle study using a fluorescently labeled thrombin ACPP to demonstrate that detection of coagulation activity can be exploited for clinical detection of neuroinflammatory lesions. Protease-specific probes appear to be excellent sensors of disease activity, as we previously showed in cancer. In contrast to cancer, molecular probes to detect specific constituents of MS plaques have not been developed. ACPPs are ideal for clinical application, as they can be generated to carry a fluorescent dye, gadolinium (Gd), or both, allowing for multimodal detection of protease activity in vivo. For example, we showed that high levels of Gd were retained in tumors when Gd-labeled MMP-ACPPs were used, resulting in enhanced T1 contrast that lasted for several days. In MS, Gd-enhanced MRI remains the main clinical tool for lesion detection. More sensitive, targeted, and instructive strategies employing advanced molecular probes could significantly enhance the early detection of MS lesions, possibly even in preclinical stages. In that regard, the ACPP technology might offer an advantage over the detection of passively diffusing Gd, as it would allow local signal enhancement by cellular probe uptake, specifically in areas with increased proteolytic activity. Therefore, MRI using a Gd-fused thrombin-ACPP may improve sensitivity, as it would detect a concentrated amount of probe possibly even around a small or slowly leaking vessel, where a new lesion may initiate. Future studies will determine the pharmacokinetic properties of a Gd-labeled thrombin-specific ACPP and exploit its translation in MS. If successful, this technology could be further used for early patient diagnosis and therapeutic intervention, and also for rapid evaluation of patient response to treatments. Because BBB disruption and fibrin deposition are prominent not only in MS, but also in other CNS diseases such as Alzheimer disease, spinal cord injury, and brain trauma, sensitive molecular sensors of coagulation activity could also prove to be invaluable clinical tools for detecting early pathological manifestations in CNS injuries and neurodegenerative diseases.

**Acknowledgment**

This research was supported by National Multiple Sclerosis Society postdoctoral fellowships to D.D. and J.K.R, a
Young Investigator Award from the Race to Erase MS to D.D., DoD W81XWH-05-1-0183 Era of Hope Innovator Award to R.Y.T., NIH National Heart, Lung, and Blood Institute grant HL096126 to J.L.D., and NIH National Institute of Neurological Diseases and Stroke grants NS027177 to R.Y.T., and NS052189 and NS066361 to K.A. M.A.P. is a fellow of the Pediatric Scientist Development Program and was supported in part by research grant No. 4-FY10-461 from the March of Dimes.

We thank K. Thorn for assistance with image analysis, M. Finucane for advice on statistical analyses, and G. Howard for editorial assistance.

Authorship
D.D. and K.M.B. generated and analyzed data, and designed research; M.A.W., E.S.M., B.F., and E.S.O. performed research, analyzed data, and assisted with experimental design; J.K.R., M.A.P., and C.B. performed research and analyzed data; D.S.S. analyzed data; J.L.D. designed experiments and analyzed data; R.Y.T. and K.A. conceived the study, designed experiments, and analyzed data; D.D., K.M.B., and K.A. wrote the manuscript with assistance from the other authors.

D.D. and K.M.B. contributed equally to this work.

Potential Conflicts of Interest
M.A.W.: equity, Avelas Biosciences; patent covering ACPPs (licensee, Avelas Biosciences; royalties paid to University of California, San Diego). E.S.O.: patent on peptides whose uptake is controllable. R.Y.T.: stock, Avelas Biosciences; patents covering ACPPs (licensee, Avelas Biosciences; royalties paid to University of California, San Diego). K.A.: grants, personal fees, Lundbeck.

References
1. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477–1489.
2. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in long-standing multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994;53:625–636.
3. Makikoski BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178–201.
4. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007;204:571–582.
5. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012;3:1227.
6. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytochemical study. Brain 1991;114:557–572.
7. Adams RA, Schachtrup C, Davalos D, et al. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 2007;14:2925–2936.
8. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34:43–62.
9. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008;451:1076–1081.
10. Inoue A, Koh CS, Shimada K, et al. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol 1996;71:131–137.
11. Langer HF, Choi EY, Zhou H, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012;110:1202–1210.
12. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004;101:17867–17872.
13. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1:382–393.
14. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010;107:4311–4316.
15. Olson ES, Aguilera TA, Jiang T, et al. Activatable cell penetrating peptides targeting protease activity in cancer. Integr Biol (Camb) 2012;4:395–406.
16. Zhang M, Costa JF, Olson ES, et al. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J Biol Chem 2010;285:22532–22541.
17. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010;107:4311–4316.
18. Chen B, Friedman B, Whitney MA, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci 2012;32:7622–7631.
19. Olson ES, Whitney MA, Friedman B, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb) 2012;4:395–406.
20. Whitney M, Savarir EN, Friedman B, et al. Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation. Angew Chem Int Ed Engl 2013;52:325–330.
21. Mullins ES, Kombinck KW, Talmage KE, et al. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood 2009;113:696–704.
22. Araki T, Makikoski BV, Kliegeris A, et al. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006;65:19–25.
23. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010;107:4317–4322.
24. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol 2013;74:317–327.
25. Merlini M, Davalos D, Akassoglou K. In vivo imaging of the neovascular unit in CNS disease. Intravital 2012;1:87–94.